Latest innovations with AB-LIFE™

May 5th 2021 – 1 min read

AB-LIFE contains 3 L. plantarum strains with clinically proven benefits on high cholesterol and triglyceride levels.

AB-BIOTICS developed the probiotic blend as early as 2012, as a breakthrough natural solution for hypercholesterolemia. The outstanding, replicated clinical results with AB-LIFE™ allowed its recognition as Probiotic of the year in 2015 by Nutraingredients, and since then, the product has been commercialised in many countries worldwide, with growing support by cardiologists, general practitioners, and pharmacists alike.

AB-LIFE™ clinical evidence keeps growing since product launch, with a recent publication in Nutrients testing the product in combination with monacolin K. The clinical trial was a 12-week randomized, double-blinded, placebo-controlled study. The combination of 10 mg of monacolin K and L. plantarum strains was well tolerated and achieved a statistically significant greater reduction in LDL cholesterol and total cholesterol in the intervention group compared to the placebo, once adjusting for recent history of hypercholesterolemia treatment.

Nutraingredients shared the exciting results on their platform. You can read the Nutraingredients article here and the paper publication full text here.

A new clinical trial with AB-LIFE™ has been recently published in Nutrients

Moreover, the Food and Drug Administration has recently acknowledged AB-LIFE™ probiotic strains as Generally Recognised as Safe (GRAS). This status supports the safety and efficacy of the product, and reinforces its positioning, which describes AB-LIFE™ as the ideal complement of a healthy lifestyle.

For more information on AB-LIFE™, its clinical evidence, mechanism of action, and benefits for patients, you can check our website, or send us your questions at bdteam@ab-biotics.com

FDA has acknowledged AB-LIFE™ strains as GRAS

Authors: Claudia Prat (Marketing) and Enric Rodó (Business Development)